APM Stock Analysis
AP
Uncovered
Aptorum Group Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The firm is focused on the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The firm's segments include Therapeutics and Non-Therapeutics. Therapeutics segment is seeking to develop various drug molecules (including projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment of human disease conditions to tackle unmet needs, in particular, two of its lead projects targeting infectious disease and cancer (including orphan oncology indications). Non-Therapeutics segment encompasses three businesses, such as diagnostics projects, including a molecular-based rapid pathogen identification and detection diagnostics (RPIDD) technology, natural supplements, including NativusWell, and AML Clinic.